Prevalence and predictors of blood-brain barrier damage in the HAART era

Journal of NeuroVirology

Volumn 20, Issue 5, 2014, Pages 521-525

  Calcagno, A ^a   Alberione, M C ^a   Romito, A ^b   Imperiale, D ^b   Ghisetti, V ^c   Audagnotto, S ^a   Lipani, F ^a   Raviolo, S ^a   Di Perri, G ^a   Bonora, S ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MARIA VITTORIA HOSPITAL   (Italy)

^c AMEDEO DI SAVOIA HOSPITAL   (Italy)

Author keywords

Antiretroviral; Blood brain barrier; CD4 nadir

Indexed keywords

ETRAVIRINE; IMMUNOGLOBULIN G; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; SERUM ALBUMIN; VIRUS RNA;

ADULT; ARTICLE; BLOOD BRAIN BARRIER DAMAGE; BRAIN DAMAGE; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOGLOBULIN PRODUCTION; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; VIRUS REPLICATION; BLOOD BRAIN BARRIER; CAPILLARY PERMEABILITY; HIV INFECTIONS; MIDDLE AGED; PATHOLOGY; PREVALENCE; RETROSPECTIVE STUDY; VIROLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84910156998     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-014-0266-2     Document Type: Article

References (26)

1. Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslen M (2002) Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS 16:2145–2149
2. Abdulle S, Hagberg L, Gisslèn M (2005) Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients. HIV Med 6:164–169
3. Andersson LM, Hagbwerg L, Fuchs D, Svennerholm B, Gisslen M (2001) Increased blood brain-barrier permeability in neuroasymptomatic HIV-1-infected individuals-correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels. J Neurovirol 7:542–547
4. Blennow K, Fredman P, Wallin A, Gottfries CG, Karlsson I, Langstrom G, Skoog I, Svennerholm L, Wikkelso C (1993) Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18–88 years of age. Eur Neurol 33:129–133
5. Calcagno A, Bonora S, Simiele M et al (2011) Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brain barrier damage. AIDS 25(11):1437–9
6. Calcagno A, Cusato J, Simiele M et al (2014) High interpatient variability of raltegravir cerebrospinal fluid concentrations in HIV-positive patients: a pharmacogenetic analysis. J Antimicrob Chemother 69(1):241–5
7. Caroscio JT, Kochwa S, Sacks H, Makuku S, Cohen JA, Yahr MD (1986) Quantitative cerebrospinal fluid IgG measurements as a marker of disease activity in multiple sclerosis. Arch Neurol 43(11):1129–31
8. Chalbot S, Zetterberg H, Blennow K et al (2011) Blood-cerebrospinal fluid barrier permeability in Alzheimer’s disease. J Alzheimers Dis 25(3):505–15
9. Comabella M, Montalban X (2014) Body fluid biomarkers in multiple sclerosis. Lancet Neurol 13(1):113–26
10. Ellis et al (2011) For the CHARTER Group. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 25:1747–1751
11. Elovaara I, Iivanainen M, Valle SL, Suni J, Tervo T, Lähdevirta J (1987) CSF protein and cellular profiles in various stages of HIV infection related to neurological manifestations. J Neurol Sci 78(3):331–342
12. Hall CD, Snyder CR, Robertson KR, Messenheimer JA, Wilkins JW, Robertson WT, Whaley RA, Van der Horst C, Silverman LM (1992) Cerebrospinal fluid analysis in human immunodeficiency virus infection. Ann Clin Lab Sci 22(3):139–43
13. Ivey NS, Mac Lean AG, Lackner AA (2009) AIDS and the blood brain barrier. J Neurovirol 15(2):111–122
14. Kamat A, Lyons JL, Misra V et al (2012) Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J Acquir Immune Defic Syndr 60(3):234–43
15. Lefvert AK, Link H (1985) IgG production within the central nervous system: a critical review of proposed formulae. Ann Neurol 17(1):13–20
16. Marshall DW, Brey RL, Butzin CA, Lucey DR, Abbadessa SM, Boswell RN (1988) Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection. Arch Neurol 45:954–958
17. Marshall DW, Brey RL, Butzin CA et al (1991) CSF changes in a longitudinal study of 124 neurologically normal HIV-1-infected U.S. Air Force personnel. J Acquir Immune Defic Syndr 4(8):777–81
18. Mocroft A, Lundgren JD, Sabin ML et al (2013) Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study. PLoS Med 10(9):e1001510
19. Nakashima I, Fujihara K, Itoyama Y (1999) Oligoclonal IgG bands in Japanese multiple sclerosis patients. J Neuroimmunol 101(2):205–6
20. Petito CK, Cash KS (1992) Blood-brain barrier abnormalities in the acquired immunodeficiency syndrome: immunohistochemical localization of serum proteins in postmortem brain. Ann Neurol 32:658–666
21. Reiber H (1995) External quality assessment in clinical neurochemistry: survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF/serum quotients. Clin Chem 41(2):256–63
22. Strazza M, Pirrone V, Wigdahl B (2011) Nonnemacher MR. Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res 1399:96–115
23. Tourtellotte WW, Ma BI (1978) Multiple sclerosis: the blood-brain-barrier and the measurement of de novo central nervous system IgG synthesis. Neurology 28(9 Pt 2):76–83
24. Yilmaz A, Gisslén M, Spudich S et al (2009) Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 4(9):e6877
25. Yilmaz A, Yiannoutsos CT, Fuchs D et al (2013) Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. J Neuroinflammation 10:62
26. Zetterberg H, Jakobsson J, Redsäter M et al (2014) Blood-cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment. Psychiatry Res. doi:10.1016/j.psychres.2014.03.045